As the conjugation site for SRPK1-GSK3β binding, the spacer domain may serve as a target for specifically designed short-peptide inhibitors to reverse gefitinib resistance in patients with NSCLC. The gene discussed is GSK3B; the disease is non-small cell lung carcinoma.